Long-term follow-up of patients with hyperthyroidism due to Graves’ disease treated with methimazole. Comparison of usual treatment schedule with drug discontinuation vs continuous treatment with low methimazole doses: A retrospective study

2008 ◽  
Vol 31 (10) ◽  
pp. 866-872 ◽  
Author(s):  
E. Mazza ◽  
M. Carlini ◽  
D. Flecchia ◽  
A. Blatto ◽  
O. Zuccarini ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Continuous Treatment ◽  
Drug Discontinuation ◽  
Graves Disease ◽  
Treatment Schedule ◽  
Usual Treatment ◽  
Long Term Follow Up

Low-Dose Anti-Thyroid Medication in Graves Disease: Assessment of the Efficacy Based on a Long-Term Follow-Up (Interim Report)

2011 ◽  
pp. P1-684-P1-684
Author(s):  
Hamid Reza Bazrafshan ◽  
Friedrich Fitz ◽  
Martin Steinmair ◽  
Clemens Reichl ◽  
Mohsen Beheshti ◽  
...  
Keyword(s):  
Low Dose ◽  
Disease Assessment ◽  
Graves Disease ◽  
Interim Report ◽  
Thyroid Medication ◽  
Long Term Follow Up

Mammosomatotroph and mixed somatotroph-lactotroph adenoma in acromegaly: a retrospective study with long-term follow-up

Endocrine ◽  
2019 ◽  
Vol 66 (2) ◽  
pp. 310-318 ◽  
Author(s):  
Liang Lv ◽  
Yong Jiang ◽  
Senlin Yin ◽  
Yu Hu ◽  
Cheng Chen ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Long Term Follow Up

scholarly journals THALIDOMIDE FOR PATIENTS WITH THALASSEMIA INTERMEDIA: A RETROSPECTIVE MULTICENTER CLINICAL STUDY

2020 ◽  
Vol 12 (1) ◽  
pp. e2020021
Author(s):  
Kun Yang ◽  
Yi Wu ◽  
Yali Zhou ◽  
Tianhong Zhou ◽  
Li Wang ◽  
...  
Keyword(s):  
Blood Transfusion ◽  
Laboratory Data ◽  
Drug Discontinuation ◽  
Therapeutic Effects ◽  
Efficacy And Safety ◽  
Thalassemia Intermedia ◽  
Short Term ◽  
Long Term Follow Up

Objective: This study focused on the efficacy and safety of thalidomide for patients with thalassemia intermedia (TI) in a multicenter trial. Methods：Clinical and laboratory data of 62 patients subjected to thalidomide therapy in four centers were retrospectively analyzed. We evaluated the efficacy and safety of thalidomide in the short-term (three months) and long-term follow-up (12 and 24 months). Response to thalidomide was defined as follows: Main Responder (MaR) showing an increase in Hb level of >2.0 g/dl or removal from blood transfusion and Minor Responder (MiR) achieving elevated hemoglobin (Hb) level of 1.0-2.0 g/dl or ≥50% reduction in blood transfusion frequency. Results：The overall response rate (ORR) of 62 patients with TI was 93.5% (58/62), with MaR and MiR rates accounting for 62.9% (39/62) and 30.6% (19/62) in short-term follow-up and 66.1% (41/62) and 27.4% (17/62) in long-term follow-up, respectively. The clinical response during long-term follow-up was maintained and the Hb level remained stable during the observation period. The response was still observed in patients with dose reduction despite a slight decrease in Hb level. However, Hb decreased rapidly to the baseline level after drug discontinuation. No effect of thalidomide on spleen size in nonsplenectomized patients was evident. Minimal side-effects were documented throughout, except peripheral neurotoxicity in one patient. Nevertheless, the mean serum ferritin (SF) level was significantly increased after treatment. Conclusion: Thalidomide had significant therapeutic effects on patients with TI, and the response was sustained with acceptable short-term and long-term adverse reactions. While these preliminary results support the potential long-term efficacy and safety of thalidomide as a therapeutic agent for TI, several issues need to be addressed before its application in the clinic.

Sign in / Sign up

Export Citation Format

Share Document